Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares traded up 15.6% during trading on Monday . The company traded as high as $11.94 and last traded at $11.57. 54,091 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 240,327 shares. The stock had previously closed at $10.01.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. Leerink Partnrs upgraded Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Leerink Partners assumed coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $28.00 price objective for the company. Guggenheim reissued a "buy" rating and issued a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday, April 2nd. JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price objective for the company. Finally, TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $25.67.
View Our Latest Analysis on MAZE
Maze Therapeutics Price Performance
The firm's fifty day moving average is $9.62.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).
Institutional Trading of Maze Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers acquired a new stake in Maze Therapeutics during the 1st quarter worth approximately $80,000. Woodline Partners LP acquired a new stake in Maze Therapeutics during the 1st quarter worth approximately $10,229,000. Octagon Capital Advisors LP acquired a new stake in Maze Therapeutics during the 1st quarter worth approximately $5,153,000. Goldman Sachs Group Inc. acquired a new stake in Maze Therapeutics during the 1st quarter worth approximately $145,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Maze Therapeutics in the 1st quarter valued at approximately $57,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
